US 12,486,269 B2
Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
Hui Lei, Shanghai (CN); Cui Li, Shanghai (CN); Chunliang Lu, Shanghai (CN); Ding Xue, Shanghai (CN); Haizhen Zhang, Shanghai (CN); Zhuming Zhang, Shanghai (CN); Jian Liu, New York, NY (US); Zhe Nie, New York, NY (US); Anatoly Ruvinsky, New York, NY (US); Eric Therrien, New York, NY (US); and Evelyne Houang, New York, NY (US)
Assigned to Aconcagua Bio, Inc., South San Francisco, CA (US)
Filed by Aconcagua Bio, Inc., South San Francisco, CA (US)
Filed on Mar. 7, 2025, as Appl. No. 19/074,260.
Application 19/074,260 is a continuation of application No. PCT/US2025/015122, filed on Feb. 7, 2025.
Claims priority of application No. PCT/CN2024/076922 (WO), filed on Feb. 8, 2024; application No. PCT/CN2024/097824 (WO), filed on Jun. 6, 2024; application No. PCT/CN2024/133596 (WO), filed on Nov. 21, 2024; and application No. PCT/CN2024/141875 (WO), filed on Dec. 24, 2024.
Prior Publication US 2025/0257067 A1, Aug. 14, 2025
Int. Cl. C07D 471/14 (2006.01); A61K 31/4365 (2006.01); A61K 31/437 (2006.01); A61K 31/444 (2006.01); A61K 31/4709 (2006.01); A61K 31/4725 (2006.01); A61K 31/4985 (2006.01); A61K 31/519 (2006.01); A61K 31/5383 (2006.01); C07D 495/04 (2006.01); C07D 495/10 (2006.01); C07D 513/14 (2006.01); C07D 519/00 (2006.01)
CPC C07D 471/14 (2013.01) [A61K 31/4365 (2013.01); A61K 31/437 (2013.01); A61K 31/444 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 31/4985 (2013.01); A61K 31/519 (2013.01); A61K 31/5383 (2013.01); C07D 495/04 (2013.01); C07D 495/10 (2013.01); C07D 513/14 (2013.01); C07D 519/00 (2013.01)] 26 Claims
 
1. A compound selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.